Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Heron Therapeutics Inc (HRTX) Price & Performance

Global X Artificial Intelligence & Technology ETF
Heron Therapeutics Inc

Price performance

Price movement over the last 24 hours

Key statistics

Global X Artificial Intelligence & Technology ETF vs Heron Therapeutics Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.06, while Heron Therapeutics Inc trades at $0.43 (market cap $80.58M). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

AIQHRTX
Sector
Sector/ThematicHealth
52-Week High
$70.14$2.23
52-Week Low
$43.28$0.39
Market Cap
$80.58M
Enterprise Value
$178.48M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Artificial Intelligence & Technology ETF

AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.

The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.

Heron Therapeutics Inc

HRTX trades at $0.4339, down 1.03% today, with neutral technical signals and mixed earnings performance. The company reported a Q1 2026 loss of $0.04 per share, missing estimates, but maintains a strong gross margin of 71.12% and a low P/S ratio of 0.47. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite quarterly pressures.

Outlook remains speculative given persistent net losses and negative cash flow from operations, though analyst consensus is overwhelmingly bullish with 94.74% buy ratings. Key risks include execution challenges and competitive threats in the biotechnology sector, while potential upside hinges on achieving profitability and successful product commercialization.

Returns comparison

Trailing returns across standard periods

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX